Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$14.47 - $26.16
Next Earnings Date
May 07 2025
Next Earnings Date
May 07 2025
Latest price
Market Cap | $2.82B |
EV | $2.31B |
Shares Outstanding | 128.95M |
Beta | 0.79 |
Analyst Rating | BUY |
Analyst Target Price | $34.00 |
P/E 2025E | 16.24x |
P/Revenue 2025E | 5.06x |
Revenue | 51.70% |
EPS | 52.40% |
Operating Cash Flow | 58.40% |
Free Cash Flow | 59.20% |
Revenue | 11.50% |
EPS | 12.40% |
Operating Cash Flow | 10.90% |
Free Cash Flow | 5.60% |
Gross Margin 2025E | 84.47% |
Net Profit Margin 2025E | 32.82% |
ROE 2025E | 38.49% |
ROCE 2024 | 29.38% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Catalyst Pharmaceuticals, Inc.
CPRX
Sector
Healthcare
Industry
Biotechnology
CEO
Daly, Richard John
Employees
181
Website
www.catalystpharma.comIPO Date
2006-11-08
Headquarters
355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved